Nine biotechnology stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an “A” (“strong buy”) or “B” overall (“buy”).
Durata Therapeutics, Inc. (DRTX) ups its rating to a B (“buy”) this week after earning a C (“hold”) in the week before. In Portfolio Grader’s specific subcategory of Earnings Momentum, DRTX also gets an A. The stock price has risen 15% over the past month, better than the 1.3% decrease the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of DRTX stock.
This week, MiMedx Group, Inc. (MDXG) is showing good progress as the company’s rating jumps from a B (“buy”) last week to an A (“strong buy”). Investors seem to agree with the upgraded status of the stock and have pushed the stock up 35.8% over the past month. For more information, get Portfolio Grader’s complete analysis of MDXG stock.
ARIAD Pharmaceuticals, Inc. (ARIA) shows solid improvement this week. The company’s rating rises from a C to a B. ARIAD Pharmaceuticals is an oncology company that focuses on the discovery, development, and commercialization of medicines for cancer patients. Wall Street has pushed the stock higher by 47.9% over the past month. For more information, get Portfolio Grader’s complete analysis of ARIA stock.
Prana Biotechnology Ltd Sponsored ADR (PRAN) improves from a B to an A rating this week. Prana Biotechnology is an Australian biotechnology company which researches and develops therapeutic drugs used for treatment of Alzheimer’s Disease and other age-related degenerative disorders such as Parkinson’s Disease and cataracts. For more information, get Portfolio Grader’s complete analysis of PRAN stock.
This is a strong week for Neurocrine Biosciences, Inc. (NBIX). The company’s rating climbs to B from the previous week’s C. Neurocrine Biosciences is focused on the discovery and development of therapeutics for neuropsychiatric, neuroinflammatory, and neurodegenerative diseases and disorders. Wall Street seems to agree with the upgrade and has propelled the stock up 7.4% over the past month. For more information, get Portfolio Grader’s complete analysis of NBIX stock.
Array BioPharma (ARRY) earns a B this week, jumping up from last week’s grade of C. Array BioPharma is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, inflammatory and metabolic diseases. For more information, get Portfolio Grader’s complete analysis of ARRY stock.
Celldex Therapeutics, Inc. (CLDX) gets a higher grade this week, advancing from a B last week to an A. Celldex Therapeutics is engaged in the discovery, development and commercialization of products that harness the human immune system to prevent and treat disease. For more information, get Portfolio Grader’s complete analysis of CLDX stock.
The rating of Insmed Incorporated (INSM) moves up this week, rising from a C to a B. Insmed develops and commercializes drugs that treat metabolic diseases, endocrine disorders and oncology. Investors have pushed the stock price up 5.4% over the past month. For more information, get Portfolio Grader’s complete analysis of INSM stock.
This week, CytRx Corporation (CYTR) pushes up from a C to a B rating. CytRx is a biopharmaceutical research and development company that specializes in oncology. For more information, get Portfolio Grader’s complete analysis of CYTR stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
